跳至主要内容
临床试验/IRCT20170303032845N1
IRCT20170303032845N1招募中3 期

The Comparison of the Efficacy of Intravitreal Injection of Iranian Made Ranibizumab (Vicentis®) with Imported Ranibizumab (Lucentis®) in Patients with Diabetic Macular Edema: A phase III, Two-armed, Double-blind, Parallel, Active-controlled, and Noninferiority Clinical Randomized Trial

Aracell zist daru0 个研究点目标入组 154 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
招募中
发起方
入组人数
154

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 80 years(—)
性别
All

入选标准

  • Diabetes mellitus type 1 or 2
  • Center involving macular edema with a central subfield thickness (CST) of >300
  • Early treatment of Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity letter score of 24 to 78 (20/32 to 20/400)
  • Blood Pressure <150/100
  • Triglyceride and LDL up to 20% higher than upper normal limits
  • Pseudophakic patients are allowed to enter the study.
  • Signed written inform consent

排除标准

  • History of intravitreal injection within the past 2 months
  • History of any ocular surgery within the past 6 months
  • History of glaucoma or ocular hypertension
  • Any media opacity in the cornea, lens and vitreous body which interferes with eye examination and imaging.
  • Monocular patients
  • Pregnant or breastfeeding women
  • Proliferative diabetic retinopathy (PDR) with high-risk characteristics
  • Smoking (more than 10 cigarettes per day)
  • Use of acetazolamide tablets or intraocular pressure-lowering drops
  • Use of systemic corticosteroids or nonsteroidal anti-inflammatory eye drops (NSAIDs)

研究者

发起方
Aracell zist daru

相似试验